Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
Public ClinicalTrials.gov record NCT00650455. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe Rheumatoid Arthritis population.
Study identification
- NCT ID
- NCT00650455
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 489 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2003 (Type not available)
- Primary completion
- Jan 2005 (Actual)
- Completion
- Jan 2005 (Actual)
- Last update posted
- Jul 21, 2008
2003 – 2005
United States locations
- U.S. sites
- 52
- U.S. states
- 18
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35249-7201 | — |
| Pfizer Investigational Site | Huntsville | Alabama | 35801 | — |
| Pfizer Investigational Site | Glendale | Arizona | 85304 | — |
| Pfizer Investigational Site | Glendale | Arizona | 85308 | — |
| Pfizer Investigational Site | Mesa | Arizona | 85202 | — |
| Pfizer Investigational Site | Paradise Valley | Arizona | 85253 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85012 | — |
| Pfizer Investigational Site | Scottsdale | Arizona | 95260 | — |
| Pfizer Investigational Site | Tucson | Arizona | 85719 | — |
| Pfizer Investigational Site | Fullerton | California | 92835 | — |
| Pfizer Investigational Site | Rancho Mirage | California | 92270 | — |
| Pfizer Investigational Site | San Diego | California | 92120 | — |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33334 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32204 | — |
| Pfizer Investigational Site | Jupiter | Florida | 33458 | — |
| Pfizer Investigational Site | Ocala | Florida | 34474 | — |
| Pfizer Investigational Site | Orlando | Florida | 32804 | — |
| Pfizer Investigational Site | Palm Harbor | Florida | 34684 | — |
| Pfizer Investigational Site | Tampa | Florida | 33614 | — |
| Pfizer Investigational Site | West Palm Beach | Florida | 33401 | — |
| Pfizer Investigational Site | Zephyrhills | Florida | 33540 | — |
| Pfizer Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60612 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62704 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46227 | — |
| Pfizer Investigational Site | Frederick | Maryland | 21702 | — |
| Pfizer Investigational Site | Greenbelt | Maryland | 20770 | — |
| Pfizer Investigational Site | Lansing | Michigan | 48910 | — |
| Pfizer Investigational Site | Jackson | Mississippi | 39216 | — |
| Pfizer Investigational Site | Marlton | New Jersey | 8053 | — |
| Pfizer Investigational Site | Passaic | New Jersey | 07055 | — |
| Pfizer Investigational Site | Teaneck | New Jersey | 07666 | — |
| Pfizer Investigational Site | Brooklyn | New York | 11203 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | New York | New York | 10035 | — |
| Pfizer Investigational Site | Columbus | Ohio | 43214 | — |
| Pfizer Investigational Site | Allentown | Pennsylvania | 18103 | — |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Erie | Pennsylvania | 16508 | — |
| Pfizer Investigational Site | Johnstown | Pennsylvania | 15904 | — |
| Pfizer Investigational Site | Mechanicsburg | Pennsylvania | 17055 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19102 | — |
| Pfizer Investigational Site | Philadephia | Pennsylvania | 19152 | — |
| Pfizer Investigational Site | Providence | Rhode Island | 02906 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | El Paso | Texas | 79902 | — |
| Pfizer Investigational Site | Fort Worth | Texas | 76107 | — |
| Pfizer Investigational Site | Plano | Texas | 75093 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78232 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78240 | — |
| Pfizer Investigational Site | Arlington | Virginia | 22204 | — |
| Pfizer Investigational Site | Seattle | Washington | 98166-2967 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00650455, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2008 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00650455 live on ClinicalTrials.gov.